Choosing The Best Amorphous Dispersion Path Before It Costs You

Developing oral small molecules increasingly requires amorphous solid dispersions (ASDs) to overcome critical solubility, stability, and food effect challenges. However, evaluating the leading ASD technologies—such as spray drying, hot melt extrusion, and KinetiSol™ Technology—sequentially or across multiple vendors often leads to costly timeline delays and fragmented data.

A more efficient path forward involves parallel screening under a single expert team. By testing multiple formulation strategies simultaneously, drug developers gain a comprehensive, unbiased view of how a molecule responds to different manufacturing conditions and excipient combinations early in development. This holistic approach ensures that downstream vulnerabilities in manufacturability, scale-up, and long-term stability are identified before entering clinical trials, ultimately protecting asset value and accelerating the timeline to market.